DE69024896T2 - Chinonderivate und ihre pharmakologische Verwendung - Google Patents

Chinonderivate und ihre pharmakologische Verwendung

Info

Publication number
DE69024896T2
DE69024896T2 DE69024896T DE69024896T DE69024896T2 DE 69024896 T2 DE69024896 T2 DE 69024896T2 DE 69024896 T DE69024896 T DE 69024896T DE 69024896 T DE69024896 T DE 69024896T DE 69024896 T2 DE69024896 T2 DE 69024896T2
Authority
DE
Germany
Prior art keywords
group
formula
pharmacologically acceptable
acceptable salts
quinone derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69024896T
Other languages
English (en)
Other versions
DE69024896D1 (de
Inventor
Shinya Abe
Yasunori Akita
Shigeki Hibi
Kazuo Hirota
Ieharu Hishinuma
Tohru Horie
Koichi Katayama
Kaname Miyamoto
Junichi Nagakawa
Yasushi Okamoto
Katsuya Tagami
Takashi Yamanaka
Isao Yamatsu
Hiromitsu Yokohama
Tsutomu Yoshimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE69024896D1 publication Critical patent/DE69024896D1/de
Application granted granted Critical
Publication of DE69024896T2 publication Critical patent/DE69024896T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/55—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/38—Quinones containing —CHO or non—quinoid keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C66/00—Quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (22)

1. Chinon-Derivat, angegeben durch die folgende allgemeine Formel, und pharmakologisch annehmbare Salze davon
A - CH = - COOR²
in der A eine Gruppe ist, angegeben durch die Formel
(in der R³, R&sup4; und R&sup5;, die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, eine C&sub1;-C&sub8;-Alkylgruppe oder eine C&sub1;-C&sub8;-Alkoxygruppe bedeuten) oder eine Gruppe, angegeben durch die Formel
(in der R³, R&sup4; und R&sup5;, die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, eine C&sub1;-C&sub8;-Alkylgruppe oder eine C&sub1;-C&sub8;-Alkoxygruppe bedeuten, X und Y, die gleich oder verschieden sein können, jeweils eine Hydroxylgruppe, eine Gruppe, angegeben durch die Formel
(in der n 0 oder 1 ist und R&sup6; eine C&sub1;-C&sub8;-Alkylgruppe bedeutet) oder eine Acylgruppe ist),
R¹ eine Alkylgruppe mit 1 bis 20 Kohlenstoffatomen, eine Cycloalkylgruppe, eine Cycloalkylalkylgruppe, eine Alkenylgruppe, eine Alkinylgruppe, eine Arylalkylgruppe, eine Gruppe der Formel
in der p eine ganze Zahl von 1 bis 10 ist), eine Heteroarylalkylgruppe, eine Gruppe, angegeben durch die Formel
(in der q eine ganze Zahl von 1 bis 6 ist und B eine Gruppe ist, angegeben durch die Formel
(in der r 0 oder eine ganze Zahl von 1 bis 2 ist, R&sup7; eine C&sub1;- C&sub8;-Alkylgruppe, eine Cycloalkylgruppe oder eine Arylgruppe ist) oder eine Gruppe, angegeben durch die Formel - O - R&sup8; (in der R&sup8; eine C&sub1;-C&sub8;-Alkylgruppe oder eine Arylgruppe ist)},
oder eine Gruppe, angegeben durch die Formel (CH&sub2;-CH&sub2;-O CH&sub3; (in der s eine ganze Zahl von 1 bis 3 ist) bedeutet,
R² eine Gruppe ist, angegeben durch die Formel -OR&sup8; (in der R&sup8; ein Wasserstoffatom oder eine C&sub1;-C&sub8;-Alkylgruppe ist) oder eine Gruppe, angegeben durch die Formel
(in der R&sup9; und R¹&sup0; die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, eine C&sub1;-C&sub8;-Alkylgruppe, eine Hydroxyalkylgruppe oder eine Heteroarylgruppe ist, mit der Maßgabe, daß R&sup9; und R¹&sup0; miteinander verbunden sein können, unter Bildung eines Ringes, zusammen mit einem daran gebundenen Stickstoffatom, der zusätzlich ein Stickstoffatom und/oder ein Sauerstoffatom enthalten und substituiert sein kann).
2. Chinon-Derivat und pharmakologisch annehmbare Salze davon nach Anspruch 1, angegeben durch die Formel
in der R³, R&sup4; und R&sup5; die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, eine C&sub1;-C&sub8;-Alkylgruppe oder eine C&sub1;-C&sub8;-Alkoxygruppe bedeuten.
3. Chinon-Derivat und pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei A angegeben ist durch die Formel
in der R³, R&sup4; und R&sup5;, die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, eine C&sub1;-C&sub8;-Alkylgruppe oder eine C&sub1;-C&sub8;-Alkoxygruppe bedeuten&sub1; X und Y, die gleich oder verschieden sein können, jeweils eine Hydroxylgruppe, eine Gruppe, angegeben durch die Formel
in der n 0 oder 1 ist und R&sup6; eine C&sub1;-C&sub8;-Alkylgruppe bedeutet) oder eine Acylgruppe bedeuten.
4. Chinon-Derivat und pharmakologisch annehmbare Salze davon nach Anspruch 2 oder 3, wobei R¹ eine Alkylgruppe mit 2 bis 20 Kohlenstoffatomen ist und R eine Gruppe ist, angegeben durch die Formel -OR&sup8;, in der R&sup8; ein Wasserstoffatom oder eine C&sub1;-C&sub8;- Alkylgruppe oder eine Gruppe der Formel
(in der R&sup9; und R¹&sup0;, die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, eine C&sub1;-C&sub8;-Alkylgruppe , eine Hydroxyalkylgruppe oder eine Heteroarylqruppe ist, mit der Maßgabe, daß R&sup9; und R¹&sup0; miteinander verbunden sein können, unter Bildung eines Ringes, zusammen mit einem daran gebundenen Stickstoffatom, der zusätzlich ein Stickstoffatom und/oder ein Sauerstoffatom enthalten und substituiert sein kann) bedeutet.
5. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 4, wobei R¹ eine Hydroxylgruppe ist.
6. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R¹ eine Alkylgruppe mit 2 bis 12 Kohlenstoffatomen und R² eine Hydroxylgruppe ist.
7. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R¹ eine Alkylgruppe mit 7 bis 12 Kohlenstoffatomen und R² eine Hydroxylgruppe ist.
8. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1 wobei R¹ eine Nonylgruppe ist.
9. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 11 wobei R¹ eine Nonylgruppe und R² eine Hydroxylgruppe ist.
10. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R¹ eine 3-Methylbutylgruppe ist.
11 Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R¹ eine Cycloalkylgruppe ist.
12. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei die Cycloalkylalkylgruppe eine Cyclohexylmethylgruppe ist.
13. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R³, R&sup4; und R jeweils unabhängig eine C&sub1;-C&sub8; Alkylpruppe oder eine C&sub1;-C&sub8; Alkoxygruppe bedeulen.
14. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R³ und R&sup4; jeweils eine C&sub1;-C&sub8; Alkoxygruppe bedeuten und R&sup5; eine C&sub1;-C&sub8; Alkyloruppe ist.
19 Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1, wobei R³ und R&sup4; jeweils eine Methoxygruppe bedeuten und R&sup5; eine Methylgruppe ist.
16. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 2, wobei R³ und R&sup4; jeweils eine Methoxygruppe bedeuten, R&sup5; eine Methylgruppe, R¹ eine Nonylgruppe und R² eine Hydroxylgruppe ist.
17. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1 oder 2, wobei R³, R&sup4; und R&sup5; jeweils eine Methoxygruppe bedeuten, R² eine Hydroxylgruppe und R¹ eine 3-Methylbutyl gruppe ist.
18. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1 oder 2, wobei R³ eine Methoxygruppe, R&sup4; eine Ethoxygruppe, R&sup5; eine Methylgruppe, R¹ eine 3-Methylbutylgruppe und R² eine Hydroxylgruppe bedeutet
19. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 1 oder 2, wobei R³ eine Methoxygruppe&sub1; R&sup4; eine Ethoxygruppe, R² eine Methylgruppe R¹ eine Cyclohexylmethylgruppe und R² eine Hydroxylgruppe bedeutet.
20. Chinon-Derivat oder pharmakologisch annehmbare Salze davon nach Anspruch 3, wobei R³ und R&sup4; jeweils eine Methoxygruppe bedeutet, R&sup5; eine Methylgruppe, R¹ eine Nonylgruppe und R² eine Hydroxylgruppe bedeutet.
21. Pharmakologisches Mittel, umfassend eine pharmakologisch wirksame Menge des Chinon-Derrivats oder eines Salzes davon, wie in Anspruch 1 definiert, und einen pharmakologisch annehmbaren Träger.
22. Verwendung einer Verbindung nach einem dei Ansprüche 1 bis 20 oder des Mittels nach Anspruch 21 zur Herstellung eines Arzneimittels zur Verhütung und Behandlung von Lebererkrankungen.,
DE69024896T 1989-09-11 1990-09-05 Chinonderivate und ihre pharmakologische Verwendung Expired - Fee Related DE69024896T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23276189 1989-09-11

Publications (2)

Publication Number Publication Date
DE69024896D1 DE69024896D1 (de) 1996-02-29
DE69024896T2 true DE69024896T2 (de) 1996-06-13

Family

ID=16944337

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69024896T Expired - Fee Related DE69024896T2 (de) 1989-09-11 1990-09-05 Chinonderivate und ihre pharmakologische Verwendung

Country Status (22)

Country Link
US (2) US5210239A (de)
EP (1) EP0419905B1 (de)
JP (1) JP2919030B2 (de)
KR (1) KR920005815B1 (de)
CN (1) CN1031992C (de)
AT (1) ATE133156T1 (de)
AU (1) AU637138B2 (de)
CA (1) CA2024479C (de)
DD (1) DD299637A5 (de)
DE (1) DE69024896T2 (de)
DK (1) DK0419905T3 (de)
ES (1) ES2082811T3 (de)
FI (1) FI102273B (de)
GR (1) GR3019614T3 (de)
HU (1) HU208105B (de)
IE (1) IE903241A1 (de)
MX (1) MXPA95001266A (de)
NO (1) NO174292C (de)
NZ (1) NZ235193A (de)
PT (1) PT95266B (de)
RU (2) RU2001904C1 (de)
ZA (1) ZA907179B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329010A (en) * 1991-03-11 1994-07-12 Eisai Co., Ltd. Quinone derivatives
JPH08510057A (ja) * 1993-11-04 1996-10-22 デイド、インターナショナル、インコーポレイテッド 血液凝固の活性化部分トロンボプラスチン時間テストのための活性化剤成分としての及び血液凝固障害の検出のためのテトラヒドロキシキノン類
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
EP0801949A1 (de) * 1996-04-15 1997-10-22 Eisai Co., Ltd. Hypoglykämisches Chinonderivat
EP0813866A3 (de) * 1996-06-17 1999-01-20 Eisai Co., Ltd. Therapeutisches Mittel gegen Gelenkserkrankungen
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
BR0010700A (pt) * 1999-04-30 2002-02-13 Slil Biomedical Corp Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
BR0114701A (pt) 2000-10-26 2003-11-18 Fournier Lab Ireland Ltd Combinação de fenofibrato e coenzima q 10 para tratamento de disfunção endotelial
AU2002235126A1 (en) * 2000-11-08 2002-05-21 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
KR100836207B1 (ko) * 2001-01-18 2008-06-09 웰리켐 바이오 테크 인크. 면역 질환 치료용의 신규한 1,2-디페닐에텐 유도체
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7314953B2 (en) * 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2486303C (en) * 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CA2583700A1 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP2564843B1 (de) * 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redoxaktive Therapeutik zur Behandlung von Mitochondrialen Erkrankungen und anderen Zuständen sowie Modulation von Energie-Biomarkern
LT1933821T (lt) * 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
TWI401081B (zh) * 2007-04-30 2013-07-11 Arqule Inc 苯醌化合物的羥基磺酸鹽及其用途
CA2700274C (en) 2007-09-26 2017-08-22 Indiana University Research And Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
JP2012502064A (ja) 2008-09-10 2012-01-26 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化還元活性治療剤を用いての広汎性発達障害の処置
CN103781753B (zh) 2011-05-26 2016-08-17 印第安纳大学研究及科技有限公司 用于治疗ape1介导的疾病的醌化合物
WO2012167122A1 (en) * 2011-06-03 2012-12-06 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
EP2913321B1 (de) * 2014-02-27 2021-07-21 Emerald Health Pharmaceuticals Inc. Neuartige Cannabigerolderivate
WO2016186853A1 (en) 2015-05-21 2016-11-24 Indiana University Research & Technology Corporation Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CA3090766A1 (en) 2018-02-08 2019-08-15 Indiana University Research And Technology Corporation Targeting ocular diseases with novel ape1/ref-1 inhibitors
KR102013574B1 (ko) * 2018-10-25 2019-08-23 주식회사 바이오톡스텍 하이드로퀴논 유도체를 포함하는 비만 또는 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN113613644A (zh) 2018-12-17 2021-11-05 印第安纳大学研究与技术公司 胃肠疾病及其症状的治疗
CN112694393B (zh) * 2020-12-25 2022-06-17 浙江神洲药业有限公司 一种再生四氯苯醌的制备方法
KR102678127B1 (ko) * 2021-07-22 2024-06-25 경희대학교 산학협력단 신규한 퀴논 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808339A (en) * 1982-04-13 1989-02-28 Takeda Chemical Industries, Ltd. Benzoquinone derivatives
JPS58177934A (ja) * 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
US5286750A (en) * 1989-10-11 1994-02-15 Basf Aktiengesellschaft Phenylacetic acid derivatives and fungicides containing them

Also Published As

Publication number Publication date
ZA907179B (en) 1991-08-28
CA2024479C (en) 1997-12-30
DD299637A5 (de) 1992-04-30
NO174292B (no) 1994-01-03
PT95266B (pt) 1997-06-30
FI102273B1 (fi) 1998-11-13
GR3019614T3 (en) 1996-07-31
AU637138B2 (en) 1993-05-20
MXPA95001266A (es) 2004-08-17
ES2082811T3 (es) 1996-04-01
HUT54612A (en) 1991-03-28
FI904206A0 (fi) 1990-08-24
NZ235193A (en) 1992-04-28
US5210239A (en) 1993-05-11
JP2919030B2 (ja) 1999-07-12
RU2001904C1 (ru) 1993-10-30
CN1031992C (zh) 1996-06-12
DE69024896D1 (de) 1996-02-29
EP0419905A2 (de) 1991-04-03
KR910006200A (ko) 1991-04-27
NO903909D0 (no) 1990-09-07
ATE133156T1 (de) 1996-02-15
EP0419905B1 (de) 1996-01-17
RU2049771C1 (ru) 1995-12-10
CN1050182A (zh) 1991-03-27
PT95266A (pt) 1991-05-22
US5385942A (en) 1995-01-31
DK0419905T3 (da) 1996-05-06
IE903241A1 (en) 1991-03-27
JPH03188042A (ja) 1991-08-16
NO903909L (no) 1991-03-12
FI102273B (fi) 1998-11-13
KR920005815B1 (ko) 1992-07-20
AU6225890A (en) 1991-03-14
CA2024479A1 (en) 1991-03-12
NO174292C (no) 1994-04-13
EP0419905A3 (en) 1992-06-24
HU208105B (en) 1993-08-30

Similar Documents

Publication Publication Date Title
DE69024896T2 (de) Chinonderivate und ihre pharmakologische Verwendung
DE2814556C2 (de) Substituierte Phenylessigsäurederivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE2560549C2 (de)
DE3219244A1 (de) Sulfonatderivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
DE69217312T2 (de) Tricyclische Heterocyclen als PGE2-Antagonisten
DE69430752T2 (de) Tetracyclische verbindungen
DE69018876T2 (de) Pyridazinon-Derivate.
DE2537070C2 (de)
DE69319859T2 (de) Neue tetracyclische verbindungen
DE3784835T2 (de) Chinoxalinon-derivate.
DE68913697T2 (de) Naphthalinderivate.
DE3785104T2 (de) Pharmazeutisch nuetzliche thiazolidin-4-karbonsaeure-derivate.
EP0072960B1 (de) 1,5-Diphenylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CS226020B2 (en) Method of preparing pyridine and pyrimidine derivatives
DE69007572T2 (de) Chalkonderivate.
DE2929760C2 (de)
DE3532279A1 (de) 1,4-benzoxathiin-derivate
DE3226516A1 (de) Substituierte thiazolo(3,2-a)pyrimidine, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten
DE2316851A1 (de) Neue pyridincarbonsaeureester
DE69216124T2 (de) Chinon-Derivate
EP0156091B1 (de) Beta-Oxo-alpha-carbamoyl-pyrrolpropionitrile, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Verwendung
Holland et al. Cinnoline-3-propionic acids, a new series of orally active antiallergic substances
DE3034005C2 (de) Indolessigsäure-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
EP0094738B1 (de) Pharmazeutische Benzodioxinverbindungen und Verfahren zu deren Herstellung
EP0090353A1 (de) Pyridon-2-derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee